Physician profile
Judith E Hersh
NPI 1922152909
$2,148.18
in general payments reported to CMS, 2019-2025
25 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $403 · 2021: $75.53 · 2022: $352 · 2023: $354 · 2024: $227 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792 · Education: $66.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.17 |
| Education | $66.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $393.10 | 2022-2025 | |
| Celularity INC. | $350.00 | 2019-2020 | |
| Millicent US INC | $214.33 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Abbvie INC. | $177.81 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $137.89 | 2019-2020 | |
| Therapeuticsmd, INC. | $129.44 | 2019-2022 | |
| Avion Pharmaceuticals | $121.32 | 2019-2022 | |
| Astellas Pharma US INC | $107.44 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $106.40 | 2021-2024 | Slynd |
| Exact Sciences Corporation | $70.22 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $62.03 | 2023-2024 | Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $43.91 | 2022-2025 | |
| Pfizer INC. | $40.91 | 2019-2022 | |
| Lupin INC. | $30.00 | 2019 | |
| Mimedx Group, INC. | $20.82 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $19.29 | 2025 | Paragard T 380a |
| Organon LLC | $17.80 | 2025 | Jada System |
| Hologic Sales and Service, LLC | $17.33 | 2019 | |
| Sumitomo Pharma America, INC. | $17.00 | 2023 | Myfembree |
| Daiichi Sankyo INC. | $15.52 | 2019 | |
| Evofem Biosciences, INC. | $14.99 | 2023 | Phexxi |
| Glaxosmithkline, LLC. | $14.92 | 2022 | |
| Allergan, INC. | $12.87 | 2019 | |
| Roche Diagnostics Corporation | $12.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Hersh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.